• Sample Page

Targeting the ubiquitin–proteasome system for cancer therapy

SAPKK3

Inhibition from the VEGF/VEGF receptor (VEGFR) pathway offers failed to boost

December 4, 2018 by Katherine Lewis Leave a Comment

Inhibition from the VEGF/VEGF receptor (VEGFR) pathway offers failed to boost general success in stage III tests in individuals with glioblastoma (GBM). decreases tumor burden in Gl261 and U87 tumors weighed against cediranib therapy only. Mice bearing Gl261 (= 0.017; MEDI3617 *= 0.011; = 10). Dual therapy (= 11) resulted in a considerably higher TAK-441 … [Read more…]

Posted in: Blogging Tagged: SAPKK3, TAK-441

PCNA is monoubiquitinated in response to DNA harm and fork stalling

June 16, 2017 by Katherine Lewis Leave a Comment

PCNA is monoubiquitinated in response to DNA harm and fork stalling and then initiates recruitment of specialized polymerases in the DNA damage tolerance pathway translesion synthesis (TLS). [BPLF1 1-246]) associated with PCNA and attenuated its ubiquitination in response to fork-stalling agents UV and hydroxyurea in cultured CI-1011 cells. Moreover monoubiquitinated PCNA was deubiquitinated after incubation … [Read more…]

Posted in: Blogging Tagged: CI-1011, SAPKK3

Copyright © 2026 Targeting the ubiquitin–proteasome system for cancer therapy.

Omega Child WordPress Theme by